BCLI
insider transactionsBRAINSTORM CELL THERAPEUTICS INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$105.0K
150.0K sh · $0.70
Own New
-
Grant·A
Director
$105.0K
150.0K sh · $0.70
Own New
-
Grant·A
Director
$157.5K
225.0K sh · $0.70
Own New
-
Grant·A
Director
$105.0K
150.0K sh · $0.70
Own New
-
Grant·A
Director
$126.0K
180.0K sh · $0.70
Own New
-
Grant·A
Director
$157.5K
225.0K sh · $0.70
Own New
-
Grant·A
Chaim Lebovits KEY
President & CEO
$0
1.8M sh
Own +896%
-
Grant·A
EVP & Chief Business Officer
$0
150.0K sh
Own +219%
-
Grant·A
Alla Patlis KEY
Interim Chief Financial Offic…
$0
100.0K sh
Own +225%
-
Grant·A
Director
$0
200.0K sh
Own +457%
-
Grant·A
Director
$0
120.0K sh
Own +292%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 26, 2026 | Menghisteab Bairu | Grant A | 150.0K | $105.0K |
| Feb 26, 2026 | Anthony J. Polverino | Grant A | 150.0K | $105.0K |
| Feb 26, 2026 | Hartoun Hartounian | Grant A | 225.0K | $157.5K |
| Feb 26, 2026 | Stacy Lindborg | Grant A | 150.0K | $105.0K |
| Feb 26, 2026 | Nir Naor | Grant A | 180.0K | $126.0K |
| Feb 26, 2026 | Ibrahim B. Dagher | Grant A | 225.0K | $157.5K |
| Feb 26, 2026 | Chaim Lebovits KEY | Grant A | 1.8M | $0 |
| Feb 26, 2026 | Uri Yablonka | Grant A | 150.0K | $0 |
| Feb 26, 2026 | Alla Patlis KEY | Grant A | 100.0K | $0 |
| Feb 26, 2026 | Jacob A Frenkel | Grant A | 200.0K | $0 |
| Feb 26, 2026 | Irit Arbel | Grant A | 120.0K | $0 |
About BCLI insider trading
This page tracks insider transactions for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.